This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering
by Zacks Equity Research
Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.
3 Medtech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Strength of the base business bodes well for Quest Diagnostics (DGX).
Quest Diagnostics (DGX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Quest Diagnostics (DGX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down
by Zacks Equity Research
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.
Quest Diagnostics (DGX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.47% and 1.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Advances in Cancer Research With New Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.
Oncology Space Gains Momentum: 3 Stocks in Focus
by Zacks Equity Research
Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.
3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024
by Riya Anand
Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide long-term gains.
Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study
by Zacks Equity Research
Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.
Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics' (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.
Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics
by Zacks Equity Research
Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quest Diagnostics (DGX) to Boost Lab Services With New Buyout
by Zacks Equity Research
Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.
Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel
by Zacks Equity Research
Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.
Quest Diagnostics' (DGX) Haystack Oncology Inks New Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.
Beat the Market the Zacks Way: Shopify, Lululemon, Telos in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden
by Zacks Equity Research
Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.
DaVita HealthCare (DVA) Up 22.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business.
Quest Diagnostics' (DGX) New Pact to Scale Precision Medicine
by Zacks Equity Research
Quest Diagnostics' (DGX) will supply next-generation sequencing and enhanced RNA extraction services for Scipher's PrismRA test through a new collaboration.
Quest Diagnostics (DGX) Up 8.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics' (DGX) New Pact to Advance Cancer Screening
by Zacks Equity Research
Quest Diagnostics' (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way to check for colorectal cancer.
Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service
by Zacks Equity Research
Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.